Delivering rapid, accurate, and accessible clinical testing through
semiconductor innovation.
Novascope Biochips is committed to democratizing in-vitro diagnostics by delivering cost-competitive bio-semiconductor solutions that enable early and accurate disease detection.
Our biochips achieve ultra-high sensitivity by detecting biomolecules at extremely low concentrations because the change of electrical discharge distribution on silicon empowers Femtogram/mL precision. To ensure high specificity, we apply advanced biochemical processes, including pharmaceutical-grade bioprobe engineering, production, and surface deposition, so that each biochip is precisely tuned to its intended target.
Our semiconductor-based diagnostic platform delivers fast, highly sensitive, and highly specific results across a wide range of biomarkers. By leveraging mature-node semiconductor foundry manufacturing, we design scalable and cost-efficient chips suitable for large-scale clinical deployment.
Our proprietary analogue ASIC architecture is optimized to minimize signal interference and ensure exceptional sensitivity, while advanced surface biofunctionalization delivers molecular specificity. These capabilities enable Novascope’s molecule-agnostic bio-semiconductor chips to function as complete diagnostic solutions for unmet critical needs in medical diagnostics.
Detect at lowest concentrations
Results in minutes, not
hours
Multiple targets, single test
Minimal analyte required
DNA, proteins & small molecules
Cost-effective solutions
Novascope Biochips Inc. develops BioFET-based biosensing platforms and leverages semiconductor technology to deliver high-sensitivity, real-time diagnostic solutions. Our biochips detect biomarkers directly from low-volume samples and bridge the gap between central labs and patient care.
Our biochips are engineered with ultra-high sensitivity through optimized analogue front-end design and surface-level biological functionalization to achieve precise specificity.
This convergence of silicon engineering and biochemical science enables a new category of diagnostic infrastructure and delivers fast, accurate and accessible clinical solutions for early detection of diseases.
Incorporation
(TW, US)
Series A financing and corporate restructuring
ISO13485 compliance lab (with a clean room)
>50 employees
Sepsis and AD diagnostics obtained clinical validation
FDA Class 1 registration for the biochip and reagent designed for detection of Escherichia coli
Former Division Director at the U.S. Food and Drug Administration Office of Generic Drug, Dr. Chan brings global regulatory expertise and intellectual property leadership to the executive team.
Emily Liu is a seasoned finance professional with 25 years of experience spanning deep-tech equity research, corporate finance, and strategic consulting in Taipei and London. At Novascope, she leads financial strategy, investor relations and capital structuring.
Dr. Sun brings entrepreneurial leadership and operational strategy to Novascope. Dr. Sun oversees operational execution and corporate development, including recruitment, fundraising and partnership development.
With a PhD in Microbiology & Immunology, Dr. Eimerman combines scientific depth with industry-scale execution in molecular diagnostics product development and strategic partnering. At Novascope, he leads technology strategy, platform expansion, and global collaboration initiatives.
Novascope is a semiconductor-driven biotech company developing ultra-sensitive biochips for rapid, early disease detection and precision diagnostics
© 2026 Novascope Diagnostics Inc.
